The Role of Perlecan Domain V in Vascular Dementia
基底膜结构域 V 在血管性痴呆中的作用
基本信息
- 批准号:8796085
- 负责人:
- 金额:$ 32.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-01 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:APP-PS1AcuteAftercareAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAnimal ModelAnimalsArteriovenous malformationAstrocytesAutopsyBilateralBiochemicalBloodBlood VesselsBrainBrain PartBrain regionCarotid StenosisCell CommunicationCell physiologyCerebral Amyloid AngiopathyCognitiveComplexCouplingDementiaDevelopmentEndothelial CellsEtiologyExperimental Animal ModelExtracellular MatrixFailureFunctional disorderGene ExpressionGenerationsGrowthGrowth FactorHealthHeparan Sulfate ProteoglycanHomoHumanImmunohistochemistryImpaired cognitionInfarctionInjuryIntegrinsIschemic StrokeKnock-in MouseMethodsMusNeuronsOutcomePathologicPathologyPatientsPericytesPhenotypePlayPrevalenceProcessProtein FragmentProteinsRelative (related person)Replacement TherapyRoleStrokeTherapeuticTimeVascular Dementiaangiogenesiscerebrovascularcognitive functioncombatdiabeticgray matterhypoperfusionimprovedmouse modelneurovascular unitnovelperlecanpost strokepreventreceptorresponseresponse to injurywhite matter
项目摘要
DESCRIPTION (provided by applicant): Despite its prevalence, VaD remains woefully understudied and poorly understood, in part due to its diverse etiology. The outcome of these multiple causes of VaD, however, remains the same- disruption of the complex coupling between endothelial cells, astrocytes, pericytes, neurons, and the extracellular matrix, the components of the neurovascular unit. We hypothesize that the extracellular matrix plays a critical role in the neurovascular disruption of VaD. In particular, we have identified a biologicaly active fragment of one prominent matrix component, the heparan sulfate proteoglycan, perlecan, to play a major role in regulating endothelial cell function after experimental ischemic stroke. This fragment, termed domain V (DV), is actively generated in the stroked brain and appears to be important to the brain's response to injury inasmuch as its absence results in more significant stroke injury and worse outcome. Furthermore, DV stroke treatment after stroke enhances peri-infarct new blood growth (angiogenesis) and important component of neurorepair. As extracellular matrix remodeling is likely to occur in the vascular pathology leading to VaD, we hypothesize that DV is actively generated, plays a key role in regulating brain endothelial cell function, and may improve endothelial cell function and neurovascular coupling when administered in two experimental mouse models of VaD, the BCAS and the DB/AD models, which differentially impact white matter and gray matter, respectively. This will allow us to determine both the impact of white and gray matter endothelial cell dysfunction on VaD and DV's potential impact on it. To investigate these hypotheses, we propose three aims: Aim 1. Determine the extent and significance of DV generation in the BCAS and DB/AD mouse models. Aim 2. Determine the therapeutic potential of DV in the BCAS and DB/AD mouse models. Aim 3. Determine the extent and significance of DV generation in human autopsy brain from subjects with VaD. Successful completion of these studies will increase our understanding of the role of the extracellular matrix and angiogenesis in VaD, and support the therapeutic potential for DV.
描述(由申请人提供):尽管VaD很流行,但遗憾的是,由于其病因多样,对VaD的研究仍然很少和了解得很少。然而,这些导致VaD的多种原因的结果仍然是一样的--内皮细胞、星形胶质细胞、周细胞、神经元和细胞外基质之间的复杂耦合被破坏,细胞外基质是神经血管单位的组成部分。我们假设细胞外基质在VaD的神经血管破坏中起关键作用。特别是,我们已经确定了一个重要的基质成分,硫酸乙酰肝素蛋白多糖的生物学活性片段,Perlecan,在实验性缺血性卒中后调节内皮细胞功能方面发挥重要作用。这种被称为区域V(DV)的片段在中风的大脑中活跃地产生,似乎对大脑对损伤的反应很重要,因为它的缺失会导致更严重的中风损伤和更糟糕的结果。此外,卒中后DV卒中治疗可促进梗塞周围新生血液的生长(血管生成),也是神经修复的重要组成部分。由于细胞外基质重塑可能发生在导致VAD的血管病理过程中,我们推测DV是主动生成的,在调节脑内皮细胞功能中起关键作用,在两种VAD实验模型BCAS和DB/AD模型中应用可能改善内皮细胞功能和神经血管偶联,这两种模型分别对白质和灰质产生不同的影响。这将使我们能够确定白质和灰质内皮细胞功能障碍对VAD的影响以及DV对其的潜在影响。为了研究这些假说,我们提出了三个目标:目的1.确定DV在BCAS和DB/AD小鼠模型中产生的程度和意义。目的2.确定DV对BCAS和DB/AD小鼠模型的治疗潜力。目的3.确定VaD患者尸检脑组织中DV产生的范围和意义。这些研究的成功完成将增加我们对细胞外基质和血管生成在VAD中的作用的理解,并支持DV的治疗潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory Jaye Bix其他文献
Correction to: Promising Cerebral Blood Flow Enhancers in Acute Ischemic Stroke
- DOI:
10.1007/s12975-022-01110-8 - 发表时间:
2022-12-16 - 期刊:
- 影响因子:4.300
- 作者:
Ifechukwude Joachim Biose;Jadesola Oremosu;Somya Bhatnagar;Gregory Jaye Bix - 通讯作者:
Gregory Jaye Bix
Gregory Jaye Bix的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory Jaye Bix', 18)}}的其他基金
Perlecan Domain V as a therapeutic VCID strategy for the clearance of amyloid beta from the brain in cerebral amyloid angiopathy
Perlecan 结构域 V 作为治疗性 VCID 策略,用于清除大脑淀粉样血管病中的β淀粉样蛋白
- 批准号:
10372826 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
Interleukin-1 alpha as a novel treatment for ischemic stroke
Interleukin-1 alpha 作为缺血性中风的新型治疗方法
- 批准号:
10418778 - 财政年份:2019
- 资助金额:
$ 32.83万 - 项目类别:
Interleukin-1 alpha as a novel treatment for ischemic stroke
Interleukin-1 alpha 作为缺血性中风的新型治疗方法
- 批准号:
9923741 - 财政年份:2019
- 资助金额:
$ 32.83万 - 项目类别:
Interleukin-1 alpha as a novel treatment for ischemic stroke
Interleukin-1 alpha 作为缺血性中风的新型治疗方法
- 批准号:
9986329 - 财政年份:2019
- 资助金额:
$ 32.83万 - 项目类别:
Combination treatment of ischemic stroke with perlecan DV and neural stem cells
Perlecan DV 和神经干细胞联合治疗缺血性中风
- 批准号:
10530655 - 财政年份:2018
- 资助金额:
$ 32.83万 - 项目类别:
Combination treatment of ischemic stroke with perlecan DV and neural stem cells
Perlecan DV 和神经干细胞联合治疗缺血性中风
- 批准号:
10303027 - 财政年份:2018
- 资助金额:
$ 32.83万 - 项目类别:
Combination treatment of ischemic stroke with perlecan DV and neural stem cells
Perlecan DV 和神经干细胞联合治疗缺血性中风
- 批准号:
10055967 - 财政年份:2018
- 资助金额:
$ 32.83万 - 项目类别:
Vascular protection via alpha5beta1 integrin inhibition during neuroinflammation
神经炎症期间通过 α5β1 整合素抑制实现血管保护
- 批准号:
9201336 - 财政年份:2016
- 资助金额:
$ 32.83万 - 项目类别:
Alpha5Beta1 Integrin inhibition as a Profound Blood-Brain Barrier Stabilizing Neuroprotective Stroke Therapy
Alpha5Beta1 整合素抑制作为深层血脑屏障稳定神经保护性中风治疗
- 批准号:
9058305 - 财政年份:2015
- 资助金额:
$ 32.83万 - 项目类别:
Use of IL-1alpha to Promote Angiogenesis and Functional Recovery After Experiment
实验后使用IL-1α促进血管生成和功能恢复
- 批准号:
8767337 - 财政年份:2014
- 资助金额:
$ 32.83万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 32.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Standard Grant